Article Details
Retrieved on: 2021-07-16 09:19:21
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Truist Securities upgraded Allogene Therapeutics from a "hold" rating to a "buy" rating and increased their price objective for the company from $34.00 ...
Article found on: www.marketbeat.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here